

## Guillaume Beinse

GUILLAUME I

Hopital Cochin, 123 Boulevard du Port F

guillaume.bei

### BIOGRAPHY

Guillaume Beinse is a medical oncologist. His scientific background includes a Master of Genetics (2017) and several works achieved in translational oncology applied to gynecological oncology, predictive oncology, prognostic studies (gynecology, digestive oncology, data science, therapeutics, and geriatric oncology). Nowadays, he works as a PhD student at the Cordelier Research Center (Paris) MEPPOT team (Personalized MEDicine, Pharmacogenomics, Therapeutic Optimization, Pr LAURENT-PUIG) in the group *Translational Research and Microfluidics* (Dr V. TALY) under the direction of Prof. J. ALEXANDRE. His activity at Cochin University Hospital (Hôpital Universitaires Paris Centre, Paris, France) includes care in general oncology (mainly gynecologic oncology, sarcoma, digestive oncology, integrative oncology (supportive care, geriatric oncology), and clinical pharmacology. His research activities include translational research projects in the setting of Institut du Cancer Paris-CARPEM (gynecology, sarcoma, data science).

### Medical and academic background

- **Medecine**

>2019

#### Clinical activities

2020-2022 – Medical oncology, Hôpital Cochin, Pr Goldwasser

2020 – Intensive care, Hôpital Saint Antoine, Pr Guidet

2013-2019

**Specialized degree in Medical Oncology, Denis-Diderot University**

**Specialized degree in Clinical Pharmacology and Therapeutic Evaluation, Pierre & Marie Curie University**

#### Clinical experience (resident)

Intensive care unit, Hôpital Saint Louis, Pr Azoulay

Medical oncology, Institut Gustave Roussy, Pr Fizazi

Radiation oncology, Hôpital Saint Louis, Pr Hennequin

Clinical pharmacology, DITEP, Institut Gustave Roussy, Pr Massard,

Clinical pharmacology, CLIPP, Hôpital Henri Mondor, Pr Macquin/Pr Tournigand,

Medical oncology, Hôpital de la Pitié-Salpêtrière, Pr Spano,

Hematology, Hôpital Henri Mondor, Pr Haioun,

Geriatric oncology, Hôpital Henri Mondor, Pr Paillaud,

Medical oncology, Hôpital Cochin, Pr Goldwasser,

Medical oncology, Institut Curie, Pr Pierga,

### **Clinical research experience**

Phase I : co-investigator Clinical pharmacology, DITEP, Institut Gustave Roussy, Pr Massard

Phase I-III : Clinical pharmacology, CLIPP, Hôpital Henri Mondor, Pr Macquin/Pr Tournigand

2007-2013

**First et Second degrees in Medical School – Paris VII Denis-Diderot University**

- **Sciences**

2020-2021

**University degree in medical teaching (DIA091, Sorbonne Université, Paris Sud, UPEC)**

2019-ongoing

**PhD: Ecole Doctorale Médicament, Toxicologie, Chimie, Imageries (MTCI ED 563)**

Centre de Recherche des Cordeliers – UMR1138 – Equipe MEPPOT (Pr LAURENT-PUIG)

Scientific director : Pr J. Alexandre

Topic: development of prognostic and predictive biomarkers in endometrial carcinoma.

2018

**DITEP, Pr Massard, Institut Gustave Roussy.** Data science research group (Dr Verlingue).

**R software learnings (biostatistics, natural language processing, machine learning);**

**certified MOOC: DAT276x: Principles of Machine Learning: R Edition**

2016-2017

**Master 2: European Magistere of Genetics – Université Paris V-VII Denis-Diderot.**

Institut Cochin – INSERM U1016 Inserm – Oxidative stress, proliferation and inflammation (Pr BATTEUX)

Scientific director: Pr J. Alexandre, Pr K. Leroy.

Topic: molecular alterations associated with NRF2 activation in endometrial carcinoma.

2016

**Diplôme de l'Institut Pasteur : Analyse des Génomes (2016).**

2008-2013

**Master 1: Cellular Biology and Physiopathology- Université Paris V-VII Denis-Diderot.**

Hopital Saint Louis– INSERM UMR S718 – Granulopoïesis and leukemia process (Pr CHOMIENNE)

Scientific director: Pr. C. Chomienne

**Teaching experience**

**University teaching (Université Paris Cité)**

**Medical oncology, Hopital Cochin :** direction of medical thesis and research works. Resident supervision.

**Centre de Recherche des Cordeliers – UMR1138 – Equipe MEPPOT:** Master 2 student supervision (topic : molecular biology ; g statistical analysis ; bioinformatics).

**DITEP, Pr Massard, Institut Gustave Roussy, Data science research group: supervision of** bioinformatics and pharmacology s (IFSBM, Ecole Centrale, biology-informatic degree).

**Fédération Nationale des Centres de Lutte contre le Cancer :** teaching.

**Awards, grants, and fundings**

**Award for translational research project GINECO 2022 (ARCAGY-GINECO).** Project: Hypermethylated circulating tumor DNA in endometrial cancer.

**PhD fundings** (Direction: Pr Alexandre) : translational research funding from Groupe Hospitalo-Universitaire CRIU APHP.CUP 202 student funding from Plan Cancer (InCA/ITMO - INSERM) 2019 ; research funding “Projets Emergents” Cancéropôle (2019)

**Award “Thrombosis & Cancer”.** Publication: Circulating tumor cell count and thrombosis in metastatic breast cancer. *J Thromb H* 2017 Aug 5 (2018) (Direction : Pr Bidard).

**Master 2 fundings** (Direction: Pr ALEXANDRE, Pr LEROY). translational research funding from Association pour la Recherche cc Cancer (2016) ; research funding “Projets Emergents” La Ligue Contre le Cancer (2016)

**Main publications**

**Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometri: ovarian cancers. Beinse G,** Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blc Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J. *Br J Cancer.* 202 **IF 2022 7.6)**

**Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospec cohort.** Gorgeu V, Borghese B, Koual M, Just PA, Lefrere Belda MA, Delanoy N, Durdux C, Chapron C, Goldwasser F, Gervais C, Terris B, Badoual C, Taly V, Laurent-Puig P, Bats AS, Alexandre J, **Beinse G.** *Gynecol Oncol.* 2022 May 25:S0090-8258(22)00321 2022=5.5)

**Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma** , Borghese B, Métairie M, Just PA, Poulet G, Garinet S, Parfait B, Didelot A, Bourreau C, Agueeff N, Lavollé A, Terris B, Chapron C

Goldwasser F, Leroy K, Blons H, Laurent-Puig P, Taly V, Alexandre J. Clin Chem. 2022 Jun 1;68(6):782-793. (IF 2022=8.3)

**Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. Beinse G**, Le Frere Just PA, Bekmezian N, Koual M, Garinet S, Leroy K, Letourneur F, Lusson A, Mulot C, Le Corre D, Metairie M, Delanoy N, Blons H C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Laurent-Puig P, Borghese B, Bats AS, Alexandre J. *Gynecol 2022 Jan 12:S0090-8258(22)00006-3. (IF 2022=5.5)*

**Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicenter study.** Thietart S, **Beinse G**, Smets P, Karras A, Philipponnet C, Augusto JF, Karoui KE, Mesbah R, Titeca-Beauport D, Hamidou I PL, Maurier F, Sacre K, Cohen P, Liozon E, Blanchard-Delaunay C, Kostianovsky A, Pagnoux C, Mouthon L, Guillevin L, Terrier B, X, Group FTFVS. *J Intern Med.* 2021 Nov 10. (IF 2022=9.0)

**Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.** Velez M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudou Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, **Beinse G**. *Pharmaceuticals (Basel).* 2021 Aug 16;14(8):804. (IF : 2021=3.6)

**Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma: improve prognostic evaluation for adjuvant treatments. Beinse G**, Rance B, Just PA, Izac B, Letourneur F, Saidu NEB, Chouze Nicco C, Goldwasser F, Batteux F, Durdux C, Chapron C, Pasmant E, Leroy K, Alexandre J, Borghese B. *Int J Gynecol Cancer.* 2020 May;30(5):640-647 (IF 2020=3.4)

**Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.** Beinse G, Tellier V, Charvet V, Deutsch I, Massard C, Hollebecque A, Verlingue L. *JCO Clin Cancer Inform.* 2019 Sep;3:1-10. (indexed MEDLINE, IF pending)

**Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly Cancer PATients) cohort. Beinse G**, Reitter D, Segaux L, Carvahlo-Verlinde M, Rousseau B, Tournigand C, C T, Laurent M, Boudou-Rouquette P, Paillaud E, Canouï-Poitrine F, Caillet P; ELCAPA Study Group. *J Geriatr Oncol.* 2020 May;11(5):311-318 (IF 2020=3.6)

**Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers.** Bouaoud J\*, **Beinse G\***, Epailard N\*, Amor-Sehlil M, Bidault F, Brocheriou I, Hervé G, Spano JP, Janot Boudou-Rouquette P, Benassarou M, Schouman T, Goudot P, Malouf G, Goldwasser F, Bertolus C. *Oral Oncol.* 2019 Aug;95:79-85 (equal contribution) (IF 2019=4.0)

**Long non-coding RNAs in genitourinary malignancies: a whole new world.** Flippot R, **Beinse G**, Boilève A, Vibert J, Malouf G. *Urol.* 2019 Aug;16(8):484-504. (IF 2019=11)

**The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. Beinse G**, Just PA, Izac B, Letourneur F, Saidu NEB, Chouzenoux S, Nicco C, Goldwasser F, Pasmant E, Batteux F, Borghese B, Alexandre J, Leroy I. *Onco Targets Ther.* 2019 Mar 25;14(3):e0214416. (IF 2019=2.7)

**Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic carcinoma. Beinse G**, Hulin A, Rousseau B. *Invest New Drugs.* 2019 Dec;37(6):1289-1291. (IF 2019=3.8)

**Brain Metastases and Place of Anti-Angiogenic Therapies in Alveolar Soft Part Sarcoma: a Retrospective Analysis of the French Sarcoma Group.** Malouf G\*, **Beinse G\***, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE, Cote Blay JY, Le Cesne A. *Oncologist.* 2019 Jul;24(7):980-988. (\*equal contribution) (IF 2019=4.1)

**Circulating tumor cell count and thrombosis in metastatic breast cancer. Beinse G**, Berger F, Cottu P, Dujaric ME, Kriegel I, Lacroix MN, Diéras V, Cabel L, Pierga JY, Bidard FC. *J Thromb Haemost.* 2017 Oct;15(10):1981-1988. (IF 2017=4.9)

**Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Vienne B, **Beinse G****, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand

Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D. *J Natl Cancer Inst.* 2017 Oct 1;109(10). (IF 2017=11.0)

**A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma.** Beinse G, Emile G, Cessot A, Boudou-Rouquette P, Huillard O, Saidu NE, Borghese B, Goldwasser F, Pujade Lauraine E, Alexandre J. *Int J Gynecol Cancer.* 20 Sep;26(7):1196-200. (IF 2016=2.4)